A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer
Si Shi(First Affiliated Hospital of Guangzhou Medical University), Xianjun Yu(Fudan University Shanghai Cancer Center), Jian Zhang(Beijing Ditan Hospital), Wei Wang(Henan Normal University), Zhiyan Liang(East China University of Science and Technology), Jin Xu(Fudan University Shanghai Cancer Center), Shuiping Gao(Fudan University Shanghai Cancer Center), Wentao Pan(Sun Yat-sen University), Rujiao Liu(Fudan University Shanghai Cancer Center), Dajun Yang(Ascendis Pharma (Denmark)), Chen Liu(Kunming University of Science and Technology), Jialin Li(Fudan University Shanghai Cancer Center), Xiaohong Tian(Northwest A&F University), Xiaowu Xu(Shanghai Medical College of Fudan University), Min Zhu, Miaoyan Wei(Fudan University Shanghai Cancer Center), Yifan Zhai(ASKA Pharmaceutical (Japan)), Lichuang Men, Hengbang Wang
Cited by 1
Related Papers
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives
|Molecular Cancer|2021|2.2k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k